Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05493267 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 10, 2022 (before its estimated August 3, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study sites: 1 to 2v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Trial Details
NCT Number NCT05493267
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Collaborators: Shanghai Public Health Clinical Center, Huashan Hospital, No.85 Hospital, Changning, Shanghai, China
Conditions
(from sponsor)		 MDR-TB, Immunotherapy
Related terms Tuberculosis, Multidrug-Resistant
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov